2. Academic Validation
  3. Reactive Oxygen Species (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs: Applications in the ROS-Related Diseases

Reactive Oxygen Species (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs: Applications in the ROS-Related Diseases

  • J Med Chem. 2021 Jan 14;64(1):298-325. doi: 10.1021/acs.jmedchem.0c01704.
Pengfei Wang 1 2,  Qijie Gong 1,  Jiabao Hu 1,  Xiang Li 2,  Xiaojin Zhang 1
Affiliations

Affiliations

  • 1 Jiangsu Key Laboratory of Drug Design and Optimization, and Department of Chemistry, China Pharmaceutical University, Nanjing 211198, China.
  • 2 Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing 211198, China.
PMID: 33356214 DOI: 10.1021/acs.jmedchem.0c01704
Abstract

Elevated levels of Reactive Oxygen Species (ROS) have commonly been implicated in a variety of diseases, including Cancer, inflammation, and neurodegenerative diseases. In light of significant differences in ROS levels between the nonpathogenic and pathological tissues, an increasing number of ROS-responsive prodrugs, probes, and theranostic prodrugs have been developed for the targeted treatment and precise diagnosis of ROS-related diseases. This review will summarize and provide insight into recent advances in ROS-responsive prodrugs, fluorescent probes, and theranostic prodrugs, with applications to different ROS-related diseases and various subcellular organelle-targetable and disease-targetable features. The ROS-responsive moieties, the self-immolative linkers, and the typical activation mechanism for the ROS-responsive release are also summarized and discussed.

Figures